Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Selank: Evidence Summary
Evidence summary for Selank across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Selank overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Generalized anxiety | Tier C | 4 | Russian clinical trials show anxiolytic effects comparable to benzodiazepines without sedation; limited Western verification |
| Cognitive enhancement | Tier C | 2 | Limited evidence for memory and learning improvement from preclinical models |
| Immunomodulation | Tier D | 0 | Tuftsin-based mechanism theoretical; no human outcome trials |
References (6)
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia — Seredenin SB, et al. . Zh Nevrol Psikhiatr Im S S Korsakova (2008)
- Selank combination therapy with diazepam in anxiety disorders — Various . Zh Nevrol Psikhiatr Im S S Korsakova (2009) PMID: 28280289
- Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank . Journal of clinical pharmacology (2021) PMID: 34396551
- Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats . Bulletin of experimental biology and medicine (2019) PMID: 31625062
- Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity . Protein and peptide letters (2018) PMID: 30255741
- Tuftsin - Properties and Analogs . Current medicinal chemistry (2017) PMID: 28745220